Although its shares have lagged other vaccine makers in 2021, Pfizer could soon be poised for significant revenue growth.
Wall Street is underestimating vaccine maker Pfizer, which is primed for massive growth ahead as its Covid treatments will remain relevant for years—not to mention generate billions of dollars of revenue for the company, according to analysts at Wells Fargo.... [+]Wells Fargo recently initiated coverage of Pfizer with a “buy” rating and price target of $60 per share, implying an upside of around 16% from current levels.
Pfizer’s vaccine business alone could generate over $5 billion per year in revenue, the firm predicts, as COVID vaccines “will likely become an annual occurrence.”
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
GameStop, Stitch Fix, SentinelOne, Novavax: What to Watch When the Stock Market Opens TodayShares of Covid-19 vaccine makers were slipping; Earnings are due from GameStop.
Les mer »
When will kids under 5 be able to get a COVID-19 vaccine?The latest data on Pfizer, Moderna, and Johnson & Johnson COVID-19 vaccine trials for young kids.
Les mer »
FDA authorizes Pfizer/BioNTech Covid-19 vaccine boosters for 16- and 17-year-oldsThe US Food and Drug Administration on Thursday authorized the Pfizer/BioNTech Covid-19 vaccine for use as a booster in people ages 16 and 17. It's the first Covid-19 vaccine booster authorized for this age group in the United States.
Les mer »
FDA clears booster shot of Pfizer vaccine for 16- and 17-year-olds amid alarm over omicronNEW: FDA authorizes booster shot of the Pfizer Covid-19 vaccine for teens ages 16 and 17 for emergency use; CDC needs to sign off before the booster shots can be administered.
Les mer »
FDA Expands Pfizer COVID-19 Booster To 16- And 17-Year-OldsThe U.S. is expanding COVID-19 boosters, ruling that 16- and 17-year-olds can get a third dose of Pfizer’s vaccine.
Les mer »